Breast cancer
We now offer a breast cancer model for testing the efficacy of oncology drug candidates.
The major advantage of this model is the orthotopic implantation of the 4T1 breast cancer cells in the breast fat pad, offering a proper tissue microenvironment that is known to affect tumor properties and drug resistance, increasing the clinical relevance and predictivity over traditionally used subcutaneous models that lack the proper microenvironment.
4T1 cell line is also available for in vitro cellular assays
Future development
Meanwhile we are working to set up new models using cancer cell lines from different tissues and organs.
Breast Cancer Preclinical Evaluation Platform
A small volume of the tumor cell suspension is injected into the mammary fat pads of anesthetized female Balb-c mice. Mice are monitored daily and weight is recorded three times per week.
Tumors are expected to become palpable in about 5 days following injection, and from that point on are measured by calipers to calculate tumor volume.
Read-Out Parameters
Body weight measurements reflecting the general health status
In vivo measurements of the tumor volume reflect the progress of the pathology
Tumor weight recording at the end of the study reflects the activity of the test drug on the tumor growth
Competitive Advantage
Orthotopic implantation of 4T1 breast cancer cells offers a valid animal model for testing the efficacy of oncology drug candidates. Standardization and validation of the model by our experienced scientific personnel provides a reliable preclinical evaluation platform for the efficacy assessment of novel therapeutics.
